Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 5
Submit an article Journal homepage
194
Views
9
CrossRef citations to date
0
Altmetric
Drug Profile

Cost–effectiveness of rituximab in follicular lymphoma

Karissa M Johnston Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada; Oxford Outcomes Ltd, Vancouver, BC, Canada; Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada; Oxford Outcomes Ltd, Vancouver, BC, Canada
,
Corneliu Bolbocean Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada; School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada; Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada; School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
,
Joseph Connors Medical Oncology, University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada; Medical Oncology, University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada
&
Stuart Peacock Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada; School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada; Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada. [email protected]
Pages 569-577 | Published online: 09 Jan 2014

References

  • Vidal L, Gafter-Gvili A, Leibovici L et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J. Natl Cancer Inst. 101(4), 248–255 (2009).
  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA. Cancer J. Clin. 62(1), 10–29 (2012).
  • Bachy E, Brice P, Delarue R et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival – a study from the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol. 28(5), 822–829 (2010).
  • Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J. Clin. Oncol. 23(22), 5019–5026 (2005).
  • Gallagher CJ, Gregory WM, Jones AE et al. Follicular lymphoma: prognostic factors for response and survival. J. Clin. Oncol. 4(10), 1470–1480 (1986).
  • Johnson PW, Rohatiner AZ, Whelan JS et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J. Clin. Oncol. 13(1), 140–147 (1995).
  • Brice P, Bastion Y, Lepage E et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol. 15(3), 1110–1117 (1997).
  • Cohen Y, Solal-Céligny P, Polliack A. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance. Haematologica 88(7), 811–823 (2003).
  • Dillman RO, Chico S. Low-grade lymphomas: comparison of histologic classifications and survival rates for patients diagnosed during the last two decades. Blood 100(11), 275b–275b (2002).
  • Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J. Clin. Oncol. 23(33), 8447–8452 (2005).
  • Rohatiner AZ, Gregory WM, Peterson B et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J. Clin. Oncol. 23(10), 2215–2223 (2005).
  • Hagemeister F. Rituximab for the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 70(3), 261–272 (2010).
  • Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin. Drug Saf. 8(2), 223–235 (2009).
  • Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70(11), 1445–1476 (2010).
  • Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a Phase 3, randomised controlled trial. Lancet 377(9759), 42–51 (2011).
  • Buske C, Dreyling MH, Eimermacher H et al. Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphomplasmocytoid/ic immumocytoma (LP-IC) – results of a prospective randomized trial of the German Low grade Lymphoma Study Group (GLSG). Blood 104(11), 50a (2004).
  • Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12), 3725–3732 (2005).
  • Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4), 1417–1423 (2005).
  • Rivas-Vera S, Baez E, Sobrevilla-Calvo P et al. Is first line single agent rituximab the best treatment for indolent non-Hodgkin’s lymphoma? Update of a multicentric study comparing rituximab vs CNOP vs rituximab plus CNOP. Blood 106(11), 684a (2005).
  • Foussard C, Mounier N, Van Hoof A et al. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J. Clin. Oncol. 24(18), 424s (2006).
  • Herold M, Haas A, Srock S et al. East German Study Group Hematology and Oncology Study. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J. Clin. Oncol. 25(15), 1986–1992 (2007).
  • Salles G, Mounier N, de Guibert S et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112(13), 4824–4831 (2008).
  • Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol. 26(28), 4579–4586 (2008).
  • Ghielmini M, Schmitz SF, Cogliatti SB et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103(12), 4416–4423 (2004).
  • Hochster H, Weller E, Gascoyne RD et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized Phase III ECOG1496 Study. J. Clin. Oncol. 27(10), 1607–1614 (2009).
  • Forstpointner R, Unterhalt M, Dreyling M et al. German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108(13), 4003–4008 (2006).
  • Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma – a randomized Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23(6), 1088–1095 (2005).
  • Hainsworth JD, Litchy S, Burris HA 3rd et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J. Clin. Oncol. 20(20), 4261–4267 (2002).
  • van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized Phase 3 intergroup trial. Blood 108(10), 3295–3301 (2006).
  • van Oers MH, Van Glabbeke M, Giurgea L et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 Phase III randomized intergroup study. J. Clin. Oncol. 28(17), 2853–2858 (2010).
  • Martinelli G, Schmitz SF, Utiger U et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J. Clin. Oncol. 28(29), 4480–4484 (2010).
  • Pettengell R, Schmitz N, Gisselbrecht C et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. J. Clin. Oncol. 28(15s), (2010) (Abstract 8005).
  • Vidal L, Gafter-Gvili A, Salles G et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J. Natl Cancer Inst. 103(23), 1799–1806 (2011).
  • Solal-Céligny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk. Res. 30(Suppl. 1), S16–S21 (2006).
  • Aksoy S, Dizdar O, Hayran M, Harputluoglu H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk. Lymphoma 50(3), 357–365 (2009).
  • Knight C, Maciver F. The cost–effectiveness of rituximab in non-Hodgkin’s lymphoma. Expert Rev. Pharmacoecon. Outcomes Res. 7(4), 319–326 (2007).
  • Leppa S, Linna M, Nyman H, Taimela E. Cost–effectiveness of rituximab maintenance treatment versus autologous stem cell transplantation (ASCT) in patients with relapsed follicular lymphoma (FL). Blood 108(11), 952a (2006).
  • Maturi B, Mikhael JR, Dunlop WCN, Tilden DT, Wong L. Maintenance therapy with rituximab for follicular lymphoma is cost-effective – a Canadian perspective. Blood 108(11), 106a–107a (2006).
  • Wake B, Hyde C, Bryan S et al. Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin’s lymphoma: a systematic review and economic evaluation. Health Technol. Assess. 6(3), 1–85 (2002).
  • Sweetenham J, Hieke K, Kerrigan M et al. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin’s lymphoma in the U.K. Br. J. Haematol. 106(1), 47–54 (1999).
  • Deconinck E, Miadi-Fargier H, Pen CL, Brice P. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics 28(1), 35–46 (2010).
  • Hayslip JW, Simpson KN. Cost–effectiveness of extended adjuvant rituximab for US patients aged 65–70 years with follicular lymphoma in second remission. Clin. Lymphoma Myeloma 8(3), 166–170 (2008).
  • Kasteng F, Erlanson M, Hagberg H, Kimby E, Relander T, Lundkvist J. Cost–effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol. 47(6), 1029–1036 (2008).
  • Hornberger J, Reyes C, Lubeck D, Valente N. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk. Lymphoma 49(2), 227–236 (2008).
  • Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin’s lymphoma with or without rituximab: cost–effectiveness and value of information based on a 5-year follow-up. Ann. Oncol. 22(5), 1189–1197 (2011).
  • Pettengell R, Donatti C, Hoskin P et al. The impact of follicular lymphoma on health-related quality of life. Ann. Oncol. 19(3), 570–576 (2008).
  • Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P. Self-reported quality of life in elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy. Eur. J. Haematol. 75(2), 116–123 (2005).
  • Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Medical decision making. Med. Decis. Making 13(4), 322–338(1993).
  • Ardeshna KM, Qian WD, Smith P et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicullar lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood 116(21), 5 (2010).
  • Kahl BS, Hong F, Williams ME et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized Phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood 118(21), LBA-6 (2011).
  • Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol. 28(21), 3525–3530 (2010).
  • Salles G, Morschhauser F, Lamy T et al. Phase 1 study results of the Type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119(22), 5126–5132 (2012).
  • Younes A, Connors JM, Park SI, Hunder NNH, Ansell SM. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. Blood 118(21), 436–437 (2011).
  • Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363(19), 1812–1821 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.